首页> 美国卫生研究院文献>Oncology Letters >Interleukin-24 inhibits osteosarcoma cell migration and invasion via the JNK/c-Jun signaling pathways
【2h】

Interleukin-24 inhibits osteosarcoma cell migration and invasion via the JNK/c-Jun signaling pathways

机译:白介素24通过JNK / c-Jun信号通路抑制骨肉瘤细胞迁移和侵袭

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Approximately 25% of osteosarcoma patients present with clinically detectable metastatic disease at the time of initial diagnosis. High-dose chemotherapy and/or surgery for the treatment of primary metastatic osteosarcoma is ineffective, and <20% of patients will survive 5 years from diagnosis. Therefore, the treatment of metastases is critical for the improvement of the prognosis of primary metastatic osteosarcoma patients. We have previously observed that overexpression of interleukin-24 (IL-24) inhibits neuroblastoma cell proliferation, migration and invasion in vitro. The present study investigated whether IL-24 may be a novel agent for osteosarcoma metastasis-suppressive treatment. It was observed that IL-24 is able to inhibit migration and invasion in spontaneously metastasizing human 143B osteosarcoma cells via the c-Jun N-terminal kinase (JNK)/c-Jun signaling pathway. IL-24 was effective in inhibiting JNK and c-Jun phosphorylation to downregulate matrix metalloproteinase (MMP)-2 and MMP-9, which contributed to the suppression of cell migration and invasion. It was concluded that IL-24 may be a potent agent in the inhibition of highly metastatic 143B osteosarcoma cells, and IL-24 may have translational potential as an effective therapeutic agent for the treatment of metastatic osteosarcoma.
机译:最初诊断时,约有25%的骨肉瘤患者出现临床上可检测到的转移性疾病。大剂量化学疗法和/或手术治疗原发性转移性骨肉瘤无效,<20%的患者将从诊断中存活5年。因此,转移的治疗对于改善原发转移性骨肉瘤患者的预后至关重要。我们以前已经观察到白细胞介素24(IL-24)的过量表达抑制了神经母细胞瘤细胞的增殖,迁移和体外侵袭。本研究调查了IL-24是否可能是抑制骨肉瘤转移的新型药物。据观察,IL-24能够通过c-Jun N端激酶(JNK)/ c-Jun信号通路抑制自发转移性人143B骨肉瘤细胞的迁移和侵袭。 IL-24可有效抑制JNK和c-Jun磷酸化从而下调基质金属蛋白酶(MMP)-2和MMP-9,从而有助于抑制细胞迁移和侵袭。结论是IL-24可能是抑制高度转移的143B骨肉瘤细胞的有效剂,并且IL-24可能具有作为治疗转移性骨肉瘤的有效治疗剂的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号